Peat samples for radiocarbon analysis-problems in pollen statistics

Clicks: 1
ID: 300048
1951
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #7,375 of 8,486 articles by views in american journal of science

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 8,486 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract

Abstract

Objectives

Impairment of type I interferon (IFN-I) immunity has been reported in critically ill COVID-19 patients. This defect can be explained by the presence of circulating autoantibodies against IFN-I. We set out to improve the detection and the quantification of such antibodies (Abs) in a cohort of severe Covid-19 patients, in an effort to better document the prevalence of these Abs as the pandemics evolves and how they correlate with the clinical course of the disease.

Methods

Anti-IFN-α Abs was investigated 84 critical COVID-19 patients who were admitted to ICU at the Lyon University Hospital, France with a commercially available kit (Thermo-Fisher).

Results

Twenty-one patients out of 84 (25%) had anti-IFNα2 Ab above cut-off (>34ng/mL) in sera. A neutralizing activity against IFN-α2 was evidenced in 15 of them, suggesting that 18% of patients were positive for neutralizing anti-IFN-α and -ω auto-Abs. In addition, in most of patients with neutralizing IFN-I Abs, we noticed an impairment of the IFN-I response. However, we did not find any difference in terms of clinical characteristics or outcome between critical COVID-19 patients “with or without” neutralizing anti-IFN-α2 auto-Abs in these conditions. Finally, we detected anti-type I IFN auto-Abs in COVID-19 patients’ sera were detected throughout the ICU stay.

Conclusions

We report that 18% of severe COVID-19 patients were positive for these Anti-Type-I IFN Abs, confirming the detrimental role of these Abs on the antiviral response. Our results further support the use of recombinant type I IFNs not targeted by the auto-Abs (e.g., IFN-b) in COVID-19 patients with an impaired IFN-I response.
Reference Key
openalex_W2328848711 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Edward S. Deevey, J. E. Potzger
Journal american journal of science
Year 1951
DOI
10.2475/ajs.249.7.473
URL
https://doi.org/10.2475/ajs.249.7.473
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.